Prevalence and pattern of drug resistance mutations among antiretroviral-treated HIV-1 patients with suboptimal virological response in Malaysia

Medical Microbiology and Immunology

Volumn 195, Issue 2, 2006, Pages 107-112

  Tee, Kok Keng ^a,b   Kamarulzaman, Adeeba ^a   Ng, Kee Peng ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

CRF01_AE; Drug resistance; HIV 1; Malaysia; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE;

ADULT; AGED; ARTICLE; CHILD; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALAYSIA; MALE; PREVALENCE; PRIORITY JOURNAL; VIROLOGY; VIRUS LOAD; VIRUS MUTATION;

ADULT; AGED; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; GENE FREQUENCY; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALAYSIA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION;

EID: 33646693644     PISSN: 03008584     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00430-005-0010-x     Document Type: Article

References (28)

1. Kamarulzaman A, Petoumenos K, Lee CK, Ariffin N, Tan LH, Kaldor J, Dore G (2004) Trend in ARV use in HIV-infected patients in Kuala Lumpur, Malaysia [ThPeB7132]. Presented at: XV International AIDS Conference, Bangkok
2. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Volberding PA (2002) Antiretroviral treatment for adult HIV infection in 2002: updated recommendation of the International AIDS Society-USA Panel. JAMA 288:222-235
3. Garcia F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miro JM, Gatell JM (1999) A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study. AIDS 13:2377-2388
4. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Sattern GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 338:853-860
5. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM (1998) A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS trial. Italy, The Netherlands, Canada and Australia study. JAMA 279:930-937
6. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337:725-733
7. Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange JM, Montaner JS (2001) Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine. AIDS 15:1269-1274
8. Ross L, Johnson M, DeMasi R, Liao Q, Graham N, Shaefer M, St Clair M (2000) Viral genetic heterogeneity in HIV-1-infected individuals is associated with increasing use of HA-ART and higher viremia. AIDS 14:813-819
9. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Murray J, Patick A, Miller V, Castillo S, Pedneault L, Mellors J (2000) The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 5:41-48
10. Tee KK, Pon CK, Kamarulzaman A, Ng KP (2005) Emergence of HIV-1 CRF01_AE/B unique recombinant forms in Kuala Lumpur, Malaysia. AIDS 19:119-126
11. Beyrer C, Vancott TC, Peng NK, Artenstein A, Duriasamy G, Nagaratnam M, Saw TL, Hegerich PA, Loomis-Price LD, Hallberg PL, Ettore CA, Nelson KE (1998) HIV type 1 subtypes in Malaysia, determined with serologic assays: 1992-1996. AIDS Res Hum Retroviruses 14:1687-1691
12. Tee KK, Kamarulzaman A, Ng KP (2006) Low prevalence of genotypic drug resistance mutations among antiretroviral-naïve HIV-1 patients in Malaysia. AIDS Res Hum Retroviruses 22, (in press)
13. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD (2005) Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 13:125-131
14. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, Perrin L (1999) Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354:729-733
15. Sethi AK, Celentano DD, Gange SJ, Moore RD, Gallant JE (2003) Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Inf Dis 37:1112-1118
16. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, (2002) Swiss HIV cohort study response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36
17. Adje C, Cheingsong R, Roels TH, Maurice C, Djomand G, Verbiest W, Hertogs K, Larder B, Monga B, Peeters M, Eholie S, Bissagene E, Coulibaly M, Respess R, Wiktor SZ, Chorba T, Nkengasong JN (2001) UNAIDS HIV drug access initiative, Abidjan, Cote d'Ivoire high prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 26:501-506
18. Vergne L, Malonga-Mouellet G, Mistoul I, Mavoungou R, Mansaray H, Peeters M, Delaporte E (2002) Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries. J Acquir Immune Defic Syndr 29:165-168
19. Kantor R, Zijenah LS, Shafer RW, Mutetwa S, Johnston E, Lloyd R, von Lieven A, Israelski D, Kalzenstein DA (2002) HIV-1 subtype C reverse transcriptase and protease genotypes in Zimbabwean patients failing antiretroviral therapy. AIDS Res Hum Retroviruses 18:1407-1413
20. Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, Tebas P, Sommadossi JP, Richman DD (2000) Drug susceptibilities in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 283:229-234
21. Descamps D, Flandre P, Calvez V, Peytavin G, Meiffredy V, Collin G, Delaugerre C, Robert-Delmas S, Bazin B, Aboulker JP, Pialoux G, Raffi F, Brun-Vezinet F (2000) Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 283:205-211
22. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC (1996) Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 70:1086-1090
23. Pellegrin I, Izopet J, Reynes J, Denayrolles M, Montes B, Pellegrin JL, Massip P, Puel J, Fleury H, Segondy M (1999) Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naïve patients receiving stavudine plus didanosine combination therapy. STADI Group. AIDS 13:1705-1709
24. Coakley EP, Gillis JM, Hammer SM (2000) Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14:F9-F15
25. Nettles RE, Kieffer TL, Simmons RP, Cofrancesco J Jr, Moore RD, Gallant JE, Persaud D, Siliciano RF (2004) Genotypic resistance in HIV-1-infected patients with persistently detectable low-level viraemia while receiving highly active antiretroviral therapy. Clin Inf Dis 39:1030-1037
26. Zennou V, Mammano F, Paulous S, Mathez D, Clavel F (1998) Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 72:3300-3306
27. Alatrakchi N, Duvivier C, Costagliola D, Samri A, Marcelin A, Kamkamidze G, Astriti M, Agher R, Calvez V, Autran B, Katlama C (2005) Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 19:25-33
28. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD (2003) Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Inf Dis 37:113-128